Drug Enforcement Administration schedules needed anesthetic drug

We are pleased to share that alfaxalone, an anesthetic drug for companion animals, now has federal authorization to be marketed commercially, starting on March 31 of this year. Originally a concern shared by our American College of Anesthesia and Analgesia colleagues, we voiced our concerns with the Drug Enforcement Administration (DEA) on Feb. 10, 2014 regarding the delays in the controlled substance-scheduling process, and we know other organizations had similar communications with the DEA. As we shared in a recent post, this particular drug was approved by the Food and Drug Administration in September 2012, but 17 months later, it was still going through the DEA’s scheduling process. Given the continued need for drug availability in clinical practice, we continue to encourage expedited federal evaluations of animal drug products.

Comments are closed.